UroGen Pharma Ltd. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a sharp increase in revenue and a narrowed net loss compared to the prior-year quarter.

Key Highlights

  • Revenue of $89.001 million for the three months ended September 30, 2026, compared to $27.482 million in the same period of 2025, according to the filing.
  • Net loss of $1.462 million for Q3 2026, versus a net loss of $33.347 million in Q3 2025, as reported in the condensed consolidated statements of operations.
  • Nine-month revenue of $212.416 million for the period ended September 30, 2026, compared to $71.951 million for the same period in 2025.
  • Accumulated deficit of $999.103 million as of September 30, 2026, up from $959.716 million as of December 31, 2025.
  • Total assets of $271.873 million as of September 30, 2026, compared to $200.455 million at December 31, 2025.
  • 49,028,740 ordinary shares issued and outstanding as of September 30, 2026, with 49,047,823 shares outstanding as of October 28, 2026.
  • Long-term debt of $189.353 million as of September 30, 2026, up from $122.210 million at December 31, 2025.

UroGen Pharma Reports Q3 2026 Financial Results and Balance Sheet Position

According to the Form 10-Q filed with the SEC for the quarterly period ended September 30, 2026, UroGen Pharma Ltd. (NASDAQ:URGN) reported revenue of $89.001 million for the three months ended September 30, 2026, compared to $27.482 million in the year-earlier quarter. Gross profit for Q3 2026 was $81.499 million against cost of revenue of $7.502 million. Operating income for the quarter was $8.329 million, compared to an operating loss of $27.386 million in Q3 2025, the filing disclosed.

For the nine months ended September 30, 2026, the company reported revenue of $212.416 million and an operating loss of $11.823 million, compared to revenue of $71.951 million and an operating loss of $105.748 million in the corresponding prior-year period, according to the filing. Net loss per ordinary share on a basic and diluted basis was $0.03 for Q3 2026 and $0.78 for the nine-month period, the filing stated. Research and development expenses were $25.964 million for the quarter and $58.897 million for the nine-month period, while selling, general and administrative expenses were $47.206 million and $147.129 million, respectively.

The condensed consolidated balance sheet as of September 30, 2026 showed cash and cash equivalents of $85.564 million, accounts receivable net of $117.283 million, and total shareholders' deficit of $125.217 million. The prepaid forward obligation, carried as a non-current liability, stood at $125.034 million. The company is incorporated in Israel and classified itself as a non-accelerated filer and smaller reporting company in the filing.

What Was Disclosed

UroGen Pharma Ltd. filed its quarterly report for the period ended September 30, 2026, disclosing revenue of $89.001 million and a net loss of $1.462 million for the quarter, alongside balance sheet data showing total assets of $271.873 million and a total shareholders' deficit of $125.217 million.